113 related articles for article (PubMed ID: 7738619)
1. Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer.
Kennedy MJ; Armstrong DK; Huelskamp AM; Ohly K; Clarke BV; Colvin OM; Grochow LB; Chen TL; Davidson NE
J Clin Oncol; 1995 May; 13(5):1136-43. PubMed ID: 7738619
[TBL] [Abstract][Full Text] [Related]
2. Novobiocin in combination with high-dose chemotherapy for the treatment of advanced breast cancer: a phase 2 study.
Hahm HA; Armstrong DK; Chen TL; Grochow L; Passos-Coelho J; Goodman SN; Davidson NE; Kennedy MJ
Biol Blood Marrow Transplant; 2000; 6(3A):335-43. PubMed ID: 10905771
[TBL] [Abstract][Full Text] [Related]
3. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity.
Eder JP; Wheeler CA; Teicher BA; Schnipper LE
Cancer Res; 1991 Jan; 51(2):510-3. PubMed ID: 1985770
[TBL] [Abstract][Full Text] [Related]
5. A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer.
Williams SF; Bitran JD; Kaminer L; Westbrook C; Jacobs R; Ashenhurst J; Robin E; Purl S; Beschorner J; Schroeder C
J Clin Oncol; 1987 Feb; 5(2):260-5. PubMed ID: 3027271
[TBL] [Abstract][Full Text] [Related]
6. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W
Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160
[TBL] [Abstract][Full Text] [Related]
7. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin.
Ayash LJ; Elias A; Schwartz G; Wheeler C; Ibrahim J; Teicher BA; Reich E; Warren D; Lynch C; Richardson P; Schnipper L; Frei E; Antman K
J Clin Oncol; 1996 Nov; 14(11):2984-92. PubMed ID: 8918496
[TBL] [Abstract][Full Text] [Related]
8. [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means].
Sola Rocabert C; MesÃa R; Mendoza L; Tabernero JM; Amill B; Maroto P; Bellet M; Ojeda B; Alonso MC; Verger G
Med Clin (Barc); 1995 Oct; 105(11):407-11. PubMed ID: 7475451
[TBL] [Abstract][Full Text] [Related]
9. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.
Holland HK; Dix SP; Geller RB; Devine SM; Heffner LT; Connaghan DG; Hillyer CD; Hughes LL; Miller RL; Moore MR; Winton EF; Wingard JR
J Clin Oncol; 1996 Apr; 14(4):1156-64. PubMed ID: 8648370
[TBL] [Abstract][Full Text] [Related]
10. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients.
Eder JP; Elias A; Shea TC; Schryber SM; Teicher BA; Hunt M; Burke J; Siegel R; Schnipper LE; Frei E
J Clin Oncol; 1990 Jul; 8(7):1239-45. PubMed ID: 2162912
[TBL] [Abstract][Full Text] [Related]
11. Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Prince HM; Rischin D; Toner GC; Seymour JF; Blakey D; Gates P; Eerhard S; Chapple P; Quinn M; Brettell M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P
Bone Marrow Transplant; 2000 Nov; 26(9):955-61. PubMed ID: 11100274
[TBL] [Abstract][Full Text] [Related]
12. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
[TBL] [Abstract][Full Text] [Related]
13. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
14. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
Ayash LJ; Elias A; Wheeler C; Reich E; Schwartz G; Mazanet R; Tepler I; Warren D; Lynch C; Gonin R
J Clin Oncol; 1994 Jan; 12(1):37-44. PubMed ID: 7505807
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
[TBL] [Abstract][Full Text] [Related]
16. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
[TBL] [Abstract][Full Text] [Related]
17. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.
Antman K; Ayash L; Elias A; Wheeler C; Schwartz G; Mazanet R; Tepler I; Schnipper LE; Frei E
J Natl Cancer Inst Monogr; 1994; (16):91-4. PubMed ID: 7528031
[TBL] [Abstract][Full Text] [Related]
18. Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.
Fields KK; Elfenbein GJ; Perkins JB; Hiemenz JW; Janssen WE; Zorsky PE; Ballester OF; Kronish LE; Foody MC
Semin Oncol; 1993 Oct; 20(5 Suppl 6):59-66. PubMed ID: 8211217
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies.
Murren JR; DiStasio SA; Lorico A; McKeon A; Zuhowski EG; Egorin MJ; Sartorelli AC; Rappa G
Cancer J; 2000; 6(4):256-65. PubMed ID: 11038146
[TBL] [Abstract][Full Text] [Related]
20. High-dose thiotepa alone and in combination regimens with bone marrow support.
Antman K; Eder JP; Elias A; Ayash L; Shea TC; Weissman L; Critchlow J; Schryber SM; Begg C; Teicher BA
Semin Oncol; 1990 Feb; 17(1 Suppl 3):33-8. PubMed ID: 2106166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
